DE69434178D1 - R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon - Google Patents

R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon

Info

Publication number
DE69434178D1
DE69434178D1 DE1994634178 DE69434178T DE69434178D1 DE 69434178 D1 DE69434178 D1 DE 69434178D1 DE 1994634178 DE1994634178 DE 1994634178 DE 69434178 T DE69434178 T DE 69434178T DE 69434178 D1 DE69434178 D1 DE 69434178D1
Authority
DE
Germany
Prior art keywords
aminoindan
propargyl
subject invention
subject
esylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1994634178
Other languages
English (en)
Other versions
DE69434178T2 (de
Inventor
Moussa B H Youdim
John P M Finberg
Ruth Levy
Jeffrey Sterling
David Lerner
Tirtsah Berger-Paskin
Haim Yellin
Alex Veinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Technion Research and Development Foundation Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Technion Research and Development Foundation Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE69434178D1 publication Critical patent/DE69434178D1/de
Application granted granted Critical
Publication of DE69434178T2 publication Critical patent/DE69434178T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
DE69434178T 1993-10-18 1994-10-12 R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon Expired - Lifetime DE69434178T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13951793A 1993-10-18 1993-10-18
US139517 1993-10-18
PCT/US1994/011567 WO1995011016A1 (en) 1993-10-18 1994-10-12 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof

Publications (2)

Publication Number Publication Date
DE69434178D1 true DE69434178D1 (de) 2005-01-13
DE69434178T2 DE69434178T2 (de) 2005-12-01

Family

ID=22487049

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69434178T Expired - Lifetime DE69434178T2 (de) 1993-10-18 1994-10-12 R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon
DE200512000044 Active DE122005000044I2 (de) 1993-10-18 1994-10-12 R-Enantiomer des N-Propargyl-1-Aminoindan zur Behandlung verschiedener Krankheiten und Mesylat, Esylat und Sulfat davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE200512000044 Active DE122005000044I2 (de) 1993-10-18 1994-10-12 R-Enantiomer des N-Propargyl-1-Aminoindan zur Behandlung verschiedener Krankheiten und Mesylat, Esylat und Sulfat davon

Country Status (17)

Country Link
EP (1) EP0812190B1 (de)
JP (3) JPH09505806A (de)
AT (1) ATE284208T1 (de)
AU (1) AU1253495A (de)
CA (1) CA2174449C (de)
DE (2) DE69434178T2 (de)
DK (1) DK0812190T3 (de)
ES (1) ES2235170T3 (de)
FR (1) FR05C0033I2 (de)
HU (1) HU226138B1 (de)
IL (1) IL111240A (de)
LU (1) LU91191I2 (de)
MX (1) MXPA94008019A (de)
NL (1) NL300205I2 (de)
PT (1) PT812190E (de)
WO (1) WO1995011016A1 (de)
ZA (1) ZA948013B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
EP0738149B1 (de) * 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1996024346A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
PT814789E (pt) * 1995-03-02 2003-09-30 Scherer Technologies Inc R P Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
EP1052983A2 (de) * 1998-01-27 2000-11-22 Thomas N. Thomas Verwendung eines mao-a oder mao-b inhibitors zur behandlung der gefässerkrankungen
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
JP2003512426A (ja) 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
US7396860B2 (en) * 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (de) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
RU2404746C2 (ru) 2005-02-23 2010-11-27 Тева Фармасьютикал Индастриз, Лтд. Композиции разагилина с улучшенной однородностью содержимого
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1956904B1 (de) 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Niedrig dosierter ladostigil zur behandlung von leichter kognitiver beeinträchtigung
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US8946300B2 (en) * 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP2101570B1 (de) 2006-12-14 2013-02-13 Teva Pharmaceutical Industries, Ltd. Rasagilin-tannat
UA97502C2 (ru) 2006-12-14 2012-02-27 Тева Фармасьютікл Індастріз, Лтд. Кристаллическая твердая основа разагилина
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
CA2708820C (en) * 2007-12-24 2016-05-10 Cipla Limited Process for the synthesis of propargylated aminoindan derivatives
EP2271612B1 (de) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagilinmesylatpartikel und verfahren zu deren herstellung
WO2009141737A2 (en) * 2008-05-23 2009-11-26 Medichem, S.A. A new method for obtaining an aminoindan mesylate derivative
WO2009147430A1 (en) * 2008-06-02 2009-12-10 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
JP5639999B2 (ja) * 2008-06-02 2014-12-10 ジェネリクス・［ユーケー］・リミテッド アミンの改良調製方法
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
EP2328861A2 (de) 2008-07-11 2011-06-08 Synthon BV Polymorphe aus rasagilin-hydrochlorid
US20100041920A1 (en) * 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (de) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Neuartige Salze von Rasagilin
EP2939669A1 (de) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011080589A2 (en) 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
EP2389927A1 (de) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmazeutische Formulationen von Rasagilin
CN102464589A (zh) * 2010-11-17 2012-05-23 凯瑞斯德生化(苏州)有限公司 雷沙吉兰、其甲磺酸盐及其中间体的制备方法
US8901352B2 (en) 2011-01-13 2014-12-02 Nobel Ilaç Sanayii Ve Ticaret A.S. Method for the synthesis of rasagiline
WO2012116752A1 (en) 2011-03-03 2012-09-07 Synthon Bv Process of resolution of 1-aminoindan
EP2705021A2 (de) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagilin und pharmazeutisch zulässige salze davon
CA2851276A1 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
EP2764862A1 (de) 2013-02-06 2014-08-13 Galenicum Health S.L. Tabletten mit unmittelbarer Freisetzung von Rasagilin Hemitartrate
EP2796130A3 (de) 2013-02-06 2015-02-25 Galenicum Health S.L. Tabletten mit unmittelbarer Freisetzung von Rasagilin Hemitartrate
IN2013MU01782A (de) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
EP0252290B1 (de) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Levodopa-methyl-ester enthaltende pharmazeutische Zusammensetzungen, ihre Herstellung und therapeutische Verwendungen
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE122005000044I1 (de) 2005-12-22
EP0812190A1 (de) 1997-12-17
PT812190E (pt) 2005-04-29
HU9601012D0 (en) 1996-06-28
JP2010018626A (ja) 2010-01-28
EP0812190B1 (de) 2004-12-08
DK0812190T3 (da) 2005-04-11
EP0812190A4 (de) 1998-03-04
JP2003160481A (ja) 2003-06-03
MXPA94008019A (es) 2004-08-10
LU91191I2 (fr) 2005-10-10
CA2174449A1 (en) 1995-04-27
HU226138B1 (en) 2008-05-28
IL111240A0 (en) 1994-12-29
FR05C0033I2 (fr) 2006-12-29
DE122005000044I2 (de) 2007-09-13
NL300205I2 (nl) 2006-03-01
HUT77934A (hu) 1998-11-30
JPH09505806A (ja) 1997-06-10
WO1995011016A1 (en) 1995-04-27
AU1253495A (en) 1995-05-08
CA2174449C (en) 2007-01-16
NL300205I1 (nl) 2005-10-03
FR05C0033I1 (de) 2005-09-30
ATE284208T1 (de) 2004-12-15
ES2235170T3 (es) 2005-07-01
DE69434178T2 (de) 2005-12-01
IL111240A (en) 2001-10-31
ZA948013B (en) 1995-05-31

Similar Documents

Publication Publication Date Title
ATE284208T1 (de) R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon
MX9708977A (es) Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
ATE328590T1 (de) Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan
TW264480B (de)
WO2003041646A3 (en) L-dopa ethyl ester salts and uses thereof
HUT50343A (en) Process for producing new condensed diazepinones and pharmaceutical compositions comprising same
HUP0301134A2 (hu) Idegvédő hatású 7-hidroxiepiandroszteron alkalmazása gyógyszerkészítmények előállítására
IL101560A0 (en) Condensed diazepinones,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: RASAGILIN MESYLAT; REGISTRATION NO/DATE: EU/1/04/304/001 - EU/1/04/304/007; 20050221

Spc suppl protection certif: 12 2005 000 044

Filing date: 20050822

8364 No opposition during term of opposition
V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: RASAGILIN MESYLAT; REGISTRATION NO/DATE: EU/1/04/304/001 - EU/1/04/304/007; 20050221

Spc suppl protection certif: 12 2005 000 044

Filing date: 20050822

V457 Spc granted

Free format text: PRODUCT NAME: RASAGILIN MESYLAT; REGISTRATION NO/DATE: EU/1/04/304/001 - EU/1/04/304/007; 20050221

Spc suppl protection certif: 12 2005 000 044

Filing date: 20050822